| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
47,361,000 |
| Market
Cap: |
722.26(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$15.25 - $15.25 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Aerie Pharmaceuticals is a pharmaceutical company focused on the discovery, development and commercialization of ophthalmic therapies for the treatment of patients with eye diseases and conditions including open-angle glaucoma, dry eye, and diabetic macular edema. Rhopressa® is a once-daily eye drop designed to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Rocklatan® is a once-daily fixed-dose combination of Rhopressa® and latanoprost, a prescribed drug for the treatment of patients with open-angle glaucoma or ocular hypertension. Co. is developing AR-15512, an ophthalmic solution for the treatment of patients with dry eye disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Larocca John |
General Counsel |
• – – |
2021-02-06 |
4 |
D |
$17.68 |
$6,241 |
D/D |
(353) |
42,685 |
|
- |
|
| Anido Vicente Jr |
Chief Executive Officer |
• • – |
2021-02-06 |
4 |
D |
$17.68 |
$52,297 |
D/D |
(2,958) |
240,092 |
|
- |
|
| Larocca John |
General Counsel |
• – – |
2021-02-04 |
4 |
A |
$0.00 |
$0 |
D/D |
11,000 |
43,038 |
|
- |
|
| Rubino Richard J |
Chief Financial Officer |
• – – |
2021-02-04 |
4 |
A |
$0.00 |
$0 |
D/D |
12,000 |
357,528 |
|
- |
|
| Anido Vicente Jr |
Chief Executive Officer |
• • – |
2021-02-04 |
4 |
A |
$0.00 |
$0 |
D/D |
28,000 |
243,050 |
|
- |
|
| Kopczynski Casey C. |
Chief Scientific Officer |
• – – |
2021-02-04 |
4 |
A |
$0.00 |
$0 |
D/D |
11,000 |
207,114 |
|
- |
|
| Mitro Thomas A |
President and COO |
• – – |
2021-02-04 |
4 |
A |
$0.00 |
$0 |
D/D |
14,000 |
91,224 |
|
- |
|
| Hollander David |
Chief R&D Officer |
• – – |
2021-02-04 |
4 |
A |
$0.00 |
$0 |
D/D |
11,000 |
33,838 |
|
- |
|
| Kopczynski Casey C. |
Chief Scientific Officer |
• – – |
2020-11-11 |
4 |
AS |
$13.01 |
$295,210 |
D/D |
(22,695) |
196,114 |
|
39% |
|
| Hollander David |
Chief R&D Officer |
• – – |
2020-11-11 |
4 |
D |
$13.05 |
$28,214 |
D/D |
(2,162) |
22,838 |
|
- |
|
| Kopczynski Casey C. |
Chief Scientific Officer |
• – – |
2020-11-10 |
4 |
AS |
$13.00 |
$94,965 |
D/D |
(7,305) |
218,809 |
|
46% |
|
| Larocca John |
General Counsel |
• – – |
2020-08-14 |
4 |
D |
$12.71 |
$8,706 |
D/D |
(685) |
32,038 |
|
- |
|
| Mchugh Julie |
Director |
– • – |
2020-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
1,750 |
8,100 |
|
- |
|
| Du Toit Michael |
Director |
– • – |
2020-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
1,750 |
8,100 |
|
- |
|
| Gryska David W |
Director |
– • – |
2020-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
1,750 |
3,500 |
|
- |
|
| Croarkin Richard |
Director |
– • – |
2020-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
1,750 |
8,100 |
|
- |
|
| Mcgraw Benjamin F III |
Director |
– • – |
2020-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
1,750 |
9,800 |
|
- |
|
| Cagle Gerald D. |
Director |
– • – |
2020-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
1,750 |
18,300 |
|
- |
|
| Goldberg Murray A |
Director |
– • – |
2020-05-18 |
4 |
OE |
$3.15 |
$88,200 |
D/D |
28,000 |
36,050 |
|
- |
|
| Anido Vicente Jr |
Chief Executive Officer |
• • – |
2020-05-16 |
4 |
D |
$14.85 |
$70,454 |
D/D |
(4,746) |
215,050 |
|
- |
|
| Mitro Thomas A |
President and COO |
• – – |
2020-05-16 |
4 |
D |
$14.85 |
$34,812 |
D/D |
(2,345) |
77,224 |
|
- |
|
| Rubino Richard J |
Chief Financial Officer |
• – – |
2020-05-16 |
4 |
D |
$14.85 |
$34,485 |
D/D |
(2,323) |
345,528 |
|
- |
|
| Cagle Gerald D. |
Director |
– • – |
2020-05-08 |
4 |
S |
$15.27 |
$76,350 |
D/D |
(5,000) |
16,550 |
|
20% |
|
| Tananbaum James B. |
10% Owner |
– – • |
2020-02-27 |
4 |
S |
$17.07 |
$17,070,000 |
I/I |
(1,000,000) |
1,229,633 |
|
21% |
|
| Anido Vicente Jr |
Chief Executive Officer |
• • – |
2020-02-24 |
4 |
D |
$20.30 |
$30,998 |
D/D |
(1,527) |
219,796 |
|
- |
|
333 Records found
|
|
Page 4 of 14 |
|
|
